Press release
Targeted Protein Degradation Market to Reach $9.85 Billion by 2035
According to MarketsandMarkets Trademark , the report " Targeted Protein Degradation Market [https://www.marketsandmarkets.com/Market-Reports/targeted-protein-degradation-analysis-market-219352281.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr] by Type [PROTACs (Vepdegestrant, Bavdegalutamide), SERDs (Elacestrant), Molecular Glues (Mezigdomide), LDD, LYTAC/ATAC], Indication (Oncology, Inflammatory), Formulation (Oral), End User - Global Forecast to 2035, is projected to reach USD 9.85 billion by 2035 from USD 0.48 billion in 2025, at a CAGR of 35.4% during the forecast period.
Targeted protein degradation (TPD) is redefining the boundaries of modern drug discovery, offering a paradigm shift from inhibition to elimination of disease-causing proteins. What is accelerating this surge, and why are global pharmaceutical leaders doubling down on this emerging modality?
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219352281 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219352281&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]
Browse
* 485 Market Data Tables
* 54 Figures
* 371 Pages and in-depth TOC on " Targeted Protein Degradation Market - Global Forecast to 2035".
Why is targeted protein degradation gaining unprecedented traction across the life sciences industry?
The increasing prevalence of oncology and neurodegenerative diseases is driving demand for more precise and effective therapies. Unlike traditional small-molecule inhibitors, TPD approaches-such as PROTACs, molecular glues, and LYTACs-enable the selective degradation of disease-causing proteins, including those previously considered "undruggable." This capability is significantly expanding the therapeutic landscape and unlocking new opportunities in complex disease areas.
How are innovation and investment shaping the competitive dynamics of this market?
Strong capital inflows from pharmaceutical giants and biotech innovators are accelerating clinical pipelines, supported by promising early-phase efficacy data. Strategic partnerships and licensing agreements are further validating the commercial potential of TPD platforms. However, what challenges remain? The complexity of E3 ligase biology and limited tissue-specific ligase availability continue to pose hurdles in drug design, safety optimization, and target specificity, requiring sustained R&D focus.
What formulation trends are driving adoption?
The oral formulations segment accounted for the largest share in 2024, reflecting a clear industry shift toward patient-centric and scalable therapeutic delivery. Oral TPD therapies offer significant advantages, including improved patient compliance, favorable pharmacokinetics, and cost-efficient distribution. Advances in medicinal chemistry have addressed earlier limitations related to solubility and permeability, enabling the development of orally bioavailable degraders without compromising efficacy. As a result, oral formulations are expected to dominate future clinical pipelines and commercial launches.
Which modality is leading innovation within the TPD ecosystem?
PROTACs (PROteolysis TArgeting Chimeras) emerged as the fastest-growing segment in 2024, driven by their unique mechanism of action that leverages the ubiquitin-proteasome system to degrade target proteins. Unlike conventional therapies, PROTACs offer enhanced potency, sustained therapeutic effects, and the potential to overcome resistance mechanisms. Clinical-stage candidates such as ARV-471, ARV-110, and NX-2127 are demonstrating promising progress, particularly in oncology. Continuous advancements in linker chemistry, E3 ligase targeting, and oral optimization are further strengthening the clinical and commercial viability of this modality.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=219352281 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=219352281&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]
Where is the center of gravity for innovation and growth?
North America accounted for the largest share of the targeted protein degradation market in 2024, supported by a robust R&D ecosystem, strong funding environment, and favorable regulatory landscape. The region hosts leading biotechnology pioneers such as Arvinas, C4 Therapeutics, and Nurix Therapeutics, which are at the forefront of developing next-generation TPD platforms. Regulatory support, including fast track and orphan drug designations, is accelerating clinical development timelines and market entry.
Additionally, the presence of advanced research institutions, extensive clinical trial networks, and strong intellectual property frameworks continues to reinforce North America's leadership. Increasing investments in oncology, neurodegenerative, and autoimmune indications further highlight the region's strategic importance in shaping the future of TPD.
Who are the key players shaping competition and innovation in this market?
Key players driving market innovation include Bristol Myers Squibb, Arvinas, BeiGene, Nurix, Kymera, C4 Therapeutics, Stemline Therapeutics, AstraZeneca, F. Hoffmann-La Roche Ltd, Bayer (Vividion), Captor Therapeutics, Ranok Therapeutics, Pfizer, Novartis, and Foghorn Therapeutics. These companies are actively expanding pipelines, forming strategic alliances, and advancing platform technologies to capture emerging opportunities in this high-growth market.
Related Reports:
Cancer Biomarkers Market [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr] - Global Forecast to 2029
Nuclear Medicine Market [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=417&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr] - Global Forecast to 2030
Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=targeted-protein-degradation-market-to-reach-985-billion-by-2035]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/targeted-protein-degradation-analysis-market-219352281.html
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Targeted Protein Degradation Market to Reach $9.85 Billion by 2035 here
News-ID: 4453281 • Views: …
More Releases from ABNewswire
Non-Hodgkin Lymphoma Treatment Pipeline Accelerates as 180+ Pharma Companies Rig …
DelveInsight's, "Non-Hodgkin Lymphoma Pipeline Insight, 2026" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Non-Hodgkin Lymphoma pipeline landscape. It covers the Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Hodgkin Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in understanding the Non-Hodgkin…
ADM Endeavors (OTCQB: ADMQ) Gains Investor Attention as Earnings Ramp and Facili …
ADM Endeavors (OTCQB: ADMQ) is drawing increased investor interest following the release of its 2025 financial results, as improving profitability and major infrastructure expansion position the company for growth in 2026.
Shares recently reached an intraday high of $0.033, up 13.7% on approximately 10x its 30-day average volume, signaling rising market attention as investors respond to the company's latest developments.
For fiscal 2025, ADM Endeavors reported revenue of $5.62 million, compared to…
Latest Research on System Type in the Precision Aquaculture Market by Marketsand …
The Global Precision Aquaculture Market is projected to grow from USD 0.85 Billion in 2025 to USD 1.43 Billion by 2030, at a CAGR of 11.1%.
The report " [https://www.marketsandmarkets.com/Market-Reports/precision-aquaculture-market-242307580.html?utm_source=abnewswire.com&utm_medium=PaidPR&utm_campaign=precisionaquaculturemarket] by Sensors, Camera Systems, Control Systems, Software (On Cloud, On Premises), Services, Smart Feeding Systems, Monitoring and Control Systems, Underwater ROV Systems, Feed Optimization, Monitoring & Surveillance, Yield Analysis & Measurement, Open Aquaculture Farms and RAS Farms - Global Forecast to…
Radioligand Therapy (RLT) Market to Surpass $10.91 Billion by 2035
Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) - Global Forecast to 2035
According to MarketsandMarkets Trademark , the global Radioligand therapy market [https://www.marketsandmarkets.com/Market-Reports/radioligand-therapy-rlt-market-238791830.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr] is projected to grow from USD 3.15 billion in 2025 to USD 10.91 billion by 2035, at a CAGR of 13.2% during the forecast period. Radioligand therapy (RLT) is rapidly…
More Releases for Targeted
Targeted Alpha Therapy Market
Global Targeted Alpha Therapy Market Size, Drugs Approval, Proprietary Technologies & Clinical Trials Insight 2028 Report Highlights:
• Global Targeted Alpha Therapy Market Insight By Region
• Approved Targeted Alpha Therapy Dosage & Pricing Insight
• Number Of Targeted Alpha Therapy In Clinical Trials: > 20 Drugs
• Targeted Alpha Therapy Clinical Trials Insight By Company, Country, Indication & Phase
• Marketed Targeted Alpha Therapy Clinical Insight By Company, Country & Indication
• Targeted Alpha Therapy Proprietary Technology Platform Insights By…
Dark Truth Behind Targeted Violence
Intimidation and cyberbullying public bullying the (target)victims selected into committing the violent criminal acts if the victims mentality was broken.
The perpetrators are small fraud groups organizing misinformation with false profiles for the public to participate with public bullying while the groups stalk the victim.
San Diego California 2021-2024 plot failed federal agents on standby monitoring the targets failed at there duties of integrity while presidential elections push towards Nov 5 San…
Bispecific Antibodies: Revolutionizing Targeted Cancer Therapy
Bispecific antibodies (BsAbs) are revolutionizing targeted cancer therapy by offering a dual-targeting approach that enhances therapeutic efficacy and addresses tumor heterogeneity. These engineered antibodies are designed to recognize and bind two different antigens simultaneously, providing a more comprehensive attack on cancer cells and improving treatment outcomes.
One of the most successful examples of BsAbs is blinatumomab, which targets CD19 on B-cells and CD3 on T-cells. Blinatumomab has shown remarkable efficacy in…
Targeted Email Leads: Pioneering a New Era in Email Marketing with High-Quality, …
GREENSBORO, NC - 15 August 2024 - In the rapidly evolving digital landscape, one company is setting new standards in email marketing. Targeted Email Leads, a trailblazer in the provision of precision-targeted email lists, is offering meticulously cleaned and verified lists that cater to a wide range of applications, from B2B communications to consumer engagement and interest groups.
What sets Targeted Email Leads apart is their rigorous verification process. Each…
Tetravalent Antibody as Cancer Targeted Therapy
The advent of tetravalent antibodies marks a significant breakthrough in cancer targeted therapy, offering a sophisticated approach to tackling the complex and heterogeneous nature of tumors. These antibodies, engineered to bind to four distinct antigens or epitopes simultaneously, provide enhanced specificity and efficacy, addressing the limitations of traditional monoclonal and even bispecific antibodies.
Download Bispecific, Trispecific and Tetraspecific Antibodies Report:
https://www.kuickresearch.com/ccformF.php?t=1721642510
Cancer is a multifaceted disease characterized by diverse cell populations within a…
Targeted Advertising Solutions Market - Rising Demand from the Providers of Targ …
The rising popularity of digital channels such as mobile and online for media and entertainment, and communications, coupled with their capability to identify and benefit from tracking customer behavior accurately, have created major interest and increasing investments by advertisers on targeted advertising.
Download PDF Brochure For Future Advancements@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=47862
Organizations making an entry into the advertising value network need to effectively educate, engage, and create alertness to the advantages of targeted…
